Research by Investigator

Investigator Initiative

Allan Andersen, MD

                      

  • Risk factors for immune-related disease in individuals with substance use disorders

Aubrey Chan, MD, PhD

  • Determining the role of acid sensing channnels in neuronal activity and mouse fear response
  • The outcomes and operating characteristics of integrated inpatient med-psch units                                            

Eric Epping, MD, PhD

  • Characterization of Schizophrenia Genetic Risk Factors from Whole Exome Sequencing
  • Identification of DNA Sequence Mutations in Regions of Copy Number Variation in Schizophrenia Patients
  • Creatine Safety, Tolerability, Efficacy in Huntington's Disease

Beng Choon Ho, MD

  • Adolescent Cannabis Use, Complex Brain Network Connectivity & Schizophrenia Risk
  • High-throughput Combined Assay of Multiplex Serum Biomarkers for Schizophrenia

Karin Hoth, PhD

Doug Langbehn, MD, PhD

  • Track HD and Track-On HD
  • Statistical Design of Huntington's Disease Studies and the Analysis and Modeling of HD Data

Jeffrey Long, PhD 

  • Functional Connectivity in Premanifest Huntington's Disease (co-investigator)
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC (co-investigator)
  • Basal Ganglia Shape Analysis and Circuitry in Huntington's Disease (co-investigator)
  • Neurobiological Predictors of Huntington's Disease (PREDICT-HD) (co-investigator)

Alison Lynch, MD, MS

  • Medication for Addiction Treatment (MAT) for Opioid Use Disorder
  • Service Delivery and Treatment for Substance Use Disorders
  • Neuromodulation with Transcranial Magnetic Stimulation in the Treatment of Methamphetamine Use Disorder
  • Emotional Experiences of Polycystic Ovary Syndrome

Jacob Michaelson, PhD 

Jacob Michaelson Laboratory

  • Genetics of neurodevelopmental conditions (ASD, ID, DD)
  • Gender differences in neurodevelopmental conditions
  • Genetics of language ability
  • Machine learning to improve the interpretation of non-coding genetic variants
  • Functional and regulatory genomics in the brain

Del Miller, MD, PharmD

  • ACLAIMS (A Comparison of Long-Acting Injectiable Medications for Schizophrenia)
  • Phase III Study of an Adjunctive Medication for Patients with Schizophrenia with Persistent, Predominant Negative Symptoms
  • Phase III Study of an Adjunctive Medication for Patients with Schizophrenia with Sub-Optimally Controlled Symptoms

Alzheimer's Research

David Moser, PhD

  • Vascular Function, Cognition, and Brain MRI in Atherosclerotic Vascular Disease

Mark Niciu, MD, PhD

Mark Niciu Laboratory

  • Experimental Therapeutics of Major Mood Disorders
  • Co-occuring Psychiatric and Substance Use Disorders

Krystal Parker, PhD

Parker Lab

  • Cerebellar contribution to cognition 
  • Potential for cerebellar stimulation to rescue cognitive impairments in humans with schizophrenia

Robert Philibert, MD, PhD

  • The Effects of Smoking on DNA Methylation in Primary Human Lymphocyte
  • Examination of Genetic and GxE Effects in the Family and Community Health Studies
  • Factors Influencing the Health Behaviors of Young African American Adults
  • Using DNA Methylation to Determine Recent Alcohol Consumption Patterns
  • A Transdiciplinary Center Focused on Rural African American Families

Anthony Purgianto, MD, PhD

  • Interventional Psychiatry/ Neuromodulation (ECT, TMS, Ketamine, DBS, VNS treatments) for mood disorders
  • Neuromodulation Task Force Consensus Recommendations for TMS in Depression
  • National Network of Depression Centers

Jordan Schultz, PharmD

Schultz Lab

  • AUTO-HD: Autonomic Function in Huntington's Disease Study
  • TZ-PD: Terazosin for Parkington's Disease Study
  • TZ-HD: Terazosin for Huntington's Disease Study
  • TZ-AD: Terazosin for Alzheimer's Disease Study
  • WEAR-HD: Wearable Device in Huntington's Disease Study

Susan Shen, MD, PhD

Shen Lab

  • Bridging the gap between basic science and health services research by studying the interface of nature and nurture
  • Improving the detection and treatment of neuropsychiatric disorders by identifying cellular endophenotypes and their molecular correlates, in the context of genetic and environmental factors

Hanna E. Stevens, MD, PhD

Psychiatry and Early Neurobiological Development Laboratory

  • Pesticide exposure during neurodevelopment
  • The Influence of Placental IGF-1 Expression on Fetal Striatal Development
  • Effects of Prenatal Stree on the Striatum

Nick Trapp, MD, MD

Trapp Lab

  • University of Iowa Interventional Psychiatry Service Patient Registry
  • Cerebellar Stimulation and Cognitive Control
  • DBS for OCD
  • TMS Targeting
  • Transcranial Magnetic Stimulation Pilot Study for Methamphetamine Use Disorder

Beth Troutman, PhD

Parent-Child Interaction Therapy  

Carolyn Turvey, PhD

  • Combined Illness Management and Psychotherapy in Treating Depressed Elders
  • My HealtheVet Project: Blue Button Feature Evaluation
  • DRI Training: the Conduct of Psychosocial Care Intervention

Thomas Wassink, MD

  • A Family-Genetic Study of Language in Autism

Andrea Weber, MD, MME

  •  Training Expansion in Addiction Medicine and Medications for Addiction Treatment at the University of Iowa (TEAM-MAT-UI)

John Wemmie, MD, PhD

John Wemmie Laboratory

  • Brain pH and Acid Sensing in Depression Related Behavior
  • Modeling CO2‐Evoked Fear in Mice: Role of Acid‐Sensing Ion Channels
  • Regulation of Cerebral Blood Flow by Acid-Sensing Ion Channels (ASICs)
  • Anti-depressant Effects of Targeting ASIC1a in the Nucleus Accumbens

Aislinn Williams, MD, PhD

Williams Lab

  • Developmental pathways involved in neuropsychiatric disease
  • Voltage-gated calcium channel genes

Virginia Willour, PhD

Back to Top

  • Attempted Suicide Candidate Gene Resequencing
  • Suicide Epigenetics
  • Genetic Risk Factor for Suicidal Behavior